Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis
PR92163
LAUSANNE, Switzerland and TANGERANG, Indonesia, Oct. 7, 2021 /PRNewswire=KYODO JBN/ --
Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical
company, and Dexa Medica, a leading Indonesian pharmaceutical company, today
announced the Indonesian launch of triptorelin for the treatment of women with
gynecological disorders, particularly endometriosis. Triptorelin, marketed
under the brand name Pamorelin(R) is one of the most common
gonadotropin-releasing hormone agonists (GnRH-a) used worldwide to help women
with endometriosis reduce pain-related symptoms by inducing a low estrogen
status. Clinical research revealed pain symptom improvement with Pamorelin(R)
as being confirmed by the reduction in the volume of endometriotic nodules
during treatment vs. placebo.[1]
Endometriosis is a chronic, debilitating disease involving long-term
inflammation and the presence of functional endometrial glands and stroma
outside the uterine cavity. Having serious consequences for general and
reproductive health, pelvic endometriosis has a high incidence estimated
between 10% of reproductive aged women worldwide (approximately 190 million)
and remains underdiagnosed.[2] Furthermore, up to 49% of women reporting
chronic pelvic pain are known to suffer from endometriosis.[2] Dexa Medica's
nation-wide launch and distribution of triptorelin, as Debiopharm's exclusive
Indonesian licensee, will help patients in the region gain access to the
pain-relieving benefits of hormone suppression with Pamorelin(R).
"We naturally recognized that Dexa Medica was the ideal company to pioneer
triptorelin access to patients in Indonesia. Their high standards of ethics,
regional pharmaceutical leadership, and strong commercialization track record
and reputation align well with Debiopharm's values," stated Fabrice Paradies,
Senior Director, Business Development & Global Commercial Alliances,
Debiopharm. "This alliance with Dexa Medica is highly valued as they are
dedicated to covering Indonesia, with over 270 million people the largest
country in Southeast Asia, having the capability to manage the logistic
complexity to provide treatment access to patients in a country having a
population of over 270 million on nearly 1,000 inhabited islands."
"Medical management of endometriosis primarily aims to delay disease
progression and alleviate symptoms. Aside from infertility, the most
debilitating symptoms in women with endometriosis are pain manifested as severe
dysmenorrhea, dyspareunia, chronic pelvic pain, dysuria or dyschezia. These
symptoms also tend to worsen with repeated menstrual cycles," stated Raymond R.
Tjandrawinata, Ph.D., Director of Business and Scientific Development PT Dexa
Medica.
"We, as a leading pharmaceutical company in Indonesia, are very proud and
excited to collaborate with a globally reputed company, Debiopharm, to market
quality products such as Triptorelin which helps Indonesians to overcome health
problems related to endometriosis. Although there is currently no definitive
data, the general prevalence is around 3% - 10%, especially in women of
reproductive age in Indonesia," stated Commercial Director PT Dexa Medica, V
Hery Sutanto.
About Pamorelin(R)
Pamorelin(R) (triptorelin) is an agonist analogue of the natural
gonadotropin-releasing hormone (GnRH), the only agonist of its kind that
differs from natural GnRH by a single amino acid and works by decreasing the
amount of certain hormones in the body. Pamorelin(R) helps women to maintain
estradiol suppression, an important factor in the management and relief of
chronic pain associated with endometriosis. When the basic activation process
of the GnRH receptor is interrupted, this initiates a cascade of events leading
to the fall in pituitary luteinizing hormone (LH) and follicle stimulating
hormone (FSH) secretion, causing a low production of circulating estradiol and
progesterone. Manufactured by Debiopharm in Switzerland, this long-acting
formulation is marketed and distributed globally through regional licensees.
About Dexa Medica
PT Dexa Medica (member of Dexa Group) is a leading Indonesian research-based
pharmaceutical company, which was established on September 27th, 1969. Starting
with the export of pharmaceutical products created by Indonesian scientists in
1993, now Dexa Medica has exported pharmaceutical products to 4 continents:
Africa, America, Asia and Europe. Regarding the export of pharmaceutical
products, Dexa Medica has become a pioneer in Indonesian pharmaceutical
manufacturers entering the UK and was awarded the Primaniyarta Award from the
Indonesian government in 2017, 2018, and 2019.
Debiopharm's commitment to patients
Debiopharm aims to develop & manufacture innovative therapies that target high
unmet medical needs in oncology and infectious diseases. Bridging the gap
between disruptive discovery products and real-world patient reach, we identify
high-potential compounds and technologies for in-licensing, clinically
demonstrate their safety and efficacy and then select large pharmaceutical
commercialization partners to maximize patient access globally.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews
Debiopharm Contact
Dawn Haughton
Communication Manager
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
Dexa Medica Contact
Sonny Himawan
Head of Corporate Communications
soni.himawan@dexagroup.com
References:
1. Maggiore ULR et al. Expert Opin Pharmacother 2014 Jun;15(8):1153-79.
2. Zondervan K et al. N Engl J Med 2020;382:1244-1256
Source: Debiopharm International SA
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。